Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclical vs Taxol in recurrent ovarian, primary peritoneal, or fallopian tube cancer
2008-002668-32Phase 3Completed
- Sponsor
- Vivesto AB
- Start
- Jun 2008
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel micellar in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Vivesto AB. Primary endpoint: Primary: Change in AUC-based treatment Cav of CA-125 relative to predose Cav of CA-125. Started Jun 2008; status: completed.
02
Drugs
paclitaxel micellar
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2008-002668-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002668-32.